PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022

Summary

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets. However, while the US and Japanese markets will continue to grow, increasing cost pressures from European regulatory agencies will counteract these drivers in the EU markets.

Highlights

Key Questions Answered

- The NSCLC market will become increasingly crowded during the forecast. How will the first and second lines of therapy be impacted by the launch of new therapies?
- How will the increasing stratification of patient populations by biomarkers affect the treatment landscape?
- The unmet needs of NSCLC patients are relatively high. What unmet needs will be addressed by the launch of new treatment options during the forecast period? What unmet needs will remain?
- How will Alimta, Avastin, Iressa and Tarceva patent expirations affect overall market growth during the forecast?
- How will increasing cost consciousness among European reimbursement authorities affect market growth in the 5EU?
- How will the difficult-to-penetrate Indian and Chinese NSCLC markets be affected by launch of pipeline candidates?/

Key Findings

- Launch of emerging pipeline therapies will result in more patients receiving premium-priced drugs in the first and second lines of therapy, and market growth in the US and Japan.
- Despite the launch of new premium-priced therapies and increasing incident cases, the NSCLC market will shrink in the 5EU. This will be primarily due to loss of patent protection for most of the major branded therapies as well as increasing cost pressures from European reimbursement authorities.
- The Indian and Chinese markets will continue to be difficult to penetrate. Many emerging pipeline therapies will not launch in these markets, especially expensive biologic therapies. Generic competition, regulatory hurdles and high cost of therapies will be major barriers to growth in these markets.
- BMS’s nivolumab will emerge as the overall market leader in 2022, launching first in the second-line segment in 2016 and expanding into the first-line segment in 2019. Uptake will be driven by the drug’s promising clinical efficacy in both squamous and non-squamous patients and strong safety profile.
- After Iressa and Tarceva lose patent protection in 2019 and 2020, respectively, Boehringer Ingelheim’s afatinib will emerge as the leading therapy for EGFR-positive patients. Afatinib’s market position will be driven by high uptake in the second-line segment.
- Pfizer’s Xalkori will lose ALK-positive patient share to Novartis’ LDK378 in the second-line segment. However, Xalkori will continue to be the patient share leader in the more lucrative first line setting and will maintain the overall sales leadership over LDK378 throughout the forecast.

Scope

- Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

- Annualized NSCLC therapeutics market revenue, annual cost of therapy and treatment usage pattern data by patient segment forecast from 2012 to 2022.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the NSCLC therapeutics market

- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising 13 candidates in Phase III development are profiled.

- Analysis of the current and future market competition in the global NSCLC market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NSCLC therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Forecast drug sales in the global NSCLC therapeutics market from 2012-2022.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.

Table Of Contents

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology and Histology 27
3.1.3 NSCLC Biomarkers 28
3.1.4 Quality of Life 29
3.2 Symptoms 30
4 Epidemiology 31
4.1 Risk Factors and Comorbidities 32
4.1.1 Smokers are more likely to have lung cancer than non-smokers 33
4.1.2 Long-term exposure to radon increases the risk of lung cancer 35
4.1.3 Family history of any cancer increases lung cancer risk 35
4.1.4 TB increases the risk of lung cancer and increases mortality risk 35
4.1.5 COPD is a comorbidity that reduces lung cancer survival 36
4.1.6 Lung cancer screening programs may not be beneficial 36
4.1.7 Stage at diagnosis significantly impacts the survival of lung cancer cases 37
4.2 Global Trends 38
4.2.1 US 41
4.2.2 France 46
4.2.3 Germany 47
4.2.4 Italy 49
4.2.5 Spain 51
4.2.6 UK 53
4.2.7 Japan 54
4.2.8 China 56
4.2.9 India 58
4.3 Forecast Methodology 60
4.3.1 Sources Used 61
4.3.2 Sources Not Used 66
4.3.3 Forecast Assumptions and Methods 67
4.4 Epidemiology Forecast (2012-2022) 69
4.4.1 Incident/Prevalent Cases of NSCLC 69
4.4.2 Age-Specific Incident Cases of NSCLC 71
4.4.3 Sex-Specific Incident Cases of NSCLC 72
4.4.4 Age-Standardized Incidence Rates of NSCLC 74
4.4.5 Segmentation of NSCLC Incident Cases 75
4.5 Discussion 83
4.5.1 Limitations of the Analysis 84
4.5.2 Strengths of the Analysis 85
5 Disease Management 86
5.1 Treatment Overview 86
5.1.1 Diagnosis 87
5.1.2 Clinical Staging 88
5.1.3 Screening and Early Detection 89
5.1.4 Localized Procedures and Therapies 91
5.1.5 Systemic Chemotherapy 91
5.1.6 Targeted Therapy 92
5.2 US 94
5.2.1 Diagnosis 94
5.2.2 Clinical Practice 95
5.3 France 97
5.3.1 Diagnosis 97
5.3.2 Clinical Practice 98
5.4 Germany 99
5.4.1 Diagnosis 99
5.4.2 Clinical Practice 100
5.5 Italy 102
5.5.1 Diagnosis 102
5.5.2 Clinical Practice 102
5.6 Spain 103
5.6.1 Diagnosis 103
5.6.2 Clinical Practice 104
5.7 UK 105
5.7.1 Diagnosis 105
5.7.2 Clinical Practice 105
5.8 Japan 107
5.8.1 Diagnosis 107
5.8.2 Clinical Practice 107
5.9 China 109
5.9.1 Diagnosis 109
5.9.2 Clinical Practice 109
5.10 India 110
5.10.1 Diagnosis 110
5.10.2 Clinical Practice 111
6 Competitive Assessment 113
6.1 Overview 113
6.2 Strategic Competitor Assessment 114
6.3 Product Profiles - Major Brands, Chemotherapies 116
6.3.1 Alimta (pemetrexed disodium) 116
6.3.2 Abraxane (nab-paclitaxel) 121
6.4 Product Profiles - Major Brands, Targeted Therapies 125
6.4.1 Iressa (gefitinib) 125
6.4.2 Tarceva (erlotinib hydrochloride) 130
6.4.3 Xalkori (crizotinib) 136
6.4.4 Avastin (bevacizumab) 141
7 Opportunity and Unmet Need 145
7.1 Overview 145
7.2 Improved Overall Survival and Less Toxicity 147
7.3 Treatments for Patients with Acquired TKI Resistance 147
7.4 Better Treatment Options for Squamous Patients 148
7.5 Preventing Relapse or Recurrence 149
7.6 More Efficacious Second-Line Therapies 149
7.7 Increased Availability of Mutation Testing 150
7.8 More Cost-Effective Therapies 150
7.9 Unmet Needs Gap Analysis 151
8 Pipeline Assessment 154
8.1 Overview 154
8.2 Clinical Trial Mapping 155
8.2.1 Clinical Trials by Country 155
8.3 Clinical Trials by Phase and Trial Status 156
8.4 Promising Drugs in Clinical Development 157
8.4.1 onartuzumab (MetMab) 160
8.4.2 necitumumab (IMC-11F8) 167
8.4.3 ramucirumab (IMC-1121B) 173
8.4.4 custirsen (OGX-011) 178
8.4.5 ganetespib (STA-9090) 184
8.4.6 nintedanib (BIBF1120) 191
8.4.7 afatinib (BIBW-2992) 196
8.4.8 dacomitinib (PF-00299804) 202
8.4.9 LDK378 207
8.4.10 Yervoy (ipilimumab) 213
8.4.11 nivolumab (BMS936558) 218
8.4.12 GSK1572932A (MAGE-A3 Cancer Immunotherapeutic) 225
8.4.13 Halaven (eribulin mesylate) 230
9 Current and Future Players 234
9.1 Overview 234
9.2 Trends in Corporate Strategy 237
9.3 Company Profiles 238
9.3.1 Roche/Genentech 238
9.3.2 Pfizer 241
9.3.3 Bristol-Myers Squibb 243
9.3.4 Eli Lilly 245
9.3.5 Boehringer Ingelheim 248
9.3.6 Novartis 250
10 Market Outlook 251
10.1 Global Markets 251
10.1.1 Forecast 251
10.1.2 Drivers and Barriers - Global Issues 255
10.2 United States 258
10.2.1 Forecast 258
10.2.2 Key Events 261
10.2.3 Drivers and Barriers 262
10.3 France 265
10.3.1 Forecast 265
10.3.2 Key Events 268
10.3.3 Drivers and Barriers 269
10.4 Germany 271
10.4.1 Forecast 271
10.4.2 Key Events 274
10.4.3 Drivers and Barriers 275
10.5 Italy 277
10.5.1 Forecast 277
10.5.2 Key Events 280
10.5.3 Drivers and Barriers 281
10.6 Spain 283
10.6.1 Forecast 283
10.6.2 Key Events 285
10.6.3 Drivers and Barriers 286
10.7 United Kingdom 288
10.7.1 Forecast 288
10.7.2 Key Events 292
10.7.3 Drivers and Barriers 293
10.8 Japan 295
10.8.1 Forecast 295
10.8.2 Key Events 299
10.8.3 Drivers and Barriers 299
10.9 China 302
10.9.1 Forecast 302
10.9.2 Key Events 305
10.9.3 Drivers and Barriers 305
10.10 India 308
10.10.1 Forecast 308
10.10.2 Key Events 312
10.10.3 Drivers and Barriers 312
11 Appendix 314
11.1 Bibliography 314
11.2 Abbreviations 344
11.3 Methodology 349
11.4 Forecasting Methodology 349
11.4.1 Number of NSCLC Patients Currently Seeking Treatment 349
11.4.2 Percent Drug-treated Patients 350
11.4.3 Drugs Included in Each Therapeutic Class 350
11.4.4 Launch and Patent Expiry Dates 351
11.4.5 General Pricing Assumptions 352
11.4.6 Individual Drug Assumptions 355
11.4.7 Generic Erosion 366
11.4.8 Pricing of Pipeline Agents 366
11.5 Physicians and Specialists Included in This Study 369
11.6 Survey of Prescribing Physicians 371
11.7 About the Authors 372
11.7.1 Author 372
11.7.2 Epidemiologist 372
11.7.3 Global Head of Healthcare 373
11.8 About GlobalData 374
11.9 Disclaimer 374

List of Tables
Table 1: Symptoms of Disease NSCLC 31
Table 2: Risk Factors and Comorbidities for Lung Cancer 33
Table 3: 9MM, Age-Standardized (World) Smoking Prevalence, Men and Women, 2006 and 2009 40
Table 4: 9MM, Sources of NSCLC Incidence Data 61
Table 5: 9MM, Incident Cases of NSCLC, Men and Women Ages ?40 Years, N, Selected Years 2012-2022 69
Table 6: 9MM, Incident Cases of NSCLC, by Age, Men and Women, N (Row %), 2012 72
Table 7: 9MM, Incident Cases of NSCLC, by Sex, Ages ?40 Years, N (Row %), 2012 73
Table 8: 9MM, Incident Cases of NSCLC, by Stage at Diagnosis, Men and Women Ages ?40 Years, N (Row %), 2012 76
Table 9: 9MM, Incident Cases of NSCLC, by Histological Subtype, Ages ?40 Years, Men and Women, N (Row %) , 2012 79
Table 10: Comparison of GlobalData Forecast for Lung Cancer Incident Cases with Globocan 2008 85
Table 11: Treatment Guidelines for NSCLC 86
Table 12: Stage Definitions for NSCLC 89
Table 13: Treatment Overview by Stage of Diagnosis for NSCLC 94
Table 14: Leading Treatments for NSCLC 116
Table 15: Product Profile - Alimta (pemetrexed disodium) 117
Table 16: Alimta SWOT Analysis, 2013 120
Table 17: Global Sales Forecasts ($m) for Alimta, 2012-2022 120
Table 18: Product Profile - Abraxane (nab-paclitaxel) 122
Table 19: Abraxane SWOT Analysis, 2013 124
Table 20: Global Sales Forecasts ($m) for Abraxane, 2012-2022 125
Table 21: Product Profile - Iressa (gefitinib) 127
Table 22: Iressa SWOT Analysis, 2013 129
Table 23: Global Sales Forecasts ($m) for Iressa, 2012-2022 130
Table 24: Product Profile - Tarceva (erlotinib hydrochloride) 131
Table 25: Tarceva SWOT Analysis, 2013 135
Table 26: Global Sales Forecasts ($m) for Tarceva, 2012-2022 136
Table 27: Product Profile - Xalkori (crizotinib) 137
Table 28: Xalkori SWOT Analysis, 2013 140
Table 29: Global Sales Forecasts ($m) for Xalkori, 2012-2022 141
Table 30: Product Profile - Avastin (bevacizumab) 142
Table 31: Avastin SWOT Analysis, 2013 144
Table 32: Global Sales Forecasts ($m) for Avastin, 2012-2022 145
Table 33: Overall Unmet Needs - Current Level of Attainment 147
Table 34: Clinical Unmet Needs - Gap Analysis, 2013 152
Table 35: NSCLC - Clinical Trials by Phase and Status, 2013 157
Table 36: Non-Small Cell Lung Cancer - Phase I-II Pipeline, 2013 158
Table 37: NSCLC - Phase III Pipeline, 2013 159
Table 38: NSCLC - Advantages and Disadvantages of Therapeutic Classes 159
Table 39: Product Profile - onartuzumab (MetMab) 161
Table 40: onartuzumab SWOT Analysis, 2013 166
Table 41: Global Sales Forecasts ($m) for onartuzumab, 2012-2022 167
Table 42: Product Profile - necitumumab (IMC-11F8) 168
Table 43: necitumumab SWOT Analysis, 2013 171
Table 44: Global Sales Forecasts ($m) for necitumumab, 2012-2022 172
Table 45: Product Profile - ramucirumab (IMC-1121B) 173
Table 46: ramucirumab SWOT Analysis, 2013 176
Table 47: Global Sales Forecasts ($m) for ramucirumab, 2012-2022 177
Table 48: Product Profile - custirsen (OGX-011) 179
Table 49: custirsen SWOT Analysis, 2013 182
Table 50: Global Sales Forecasts ($m) for custirsen, 2012-2022 184
Table 51: Product Profile - ganetespib (STA-9090) 185
Table 52: ganetespib SWOT Analysis, 2013 190
Table 53: Global Sales Forecasts ($m) for ganetespib, 2012-2022 191
Table 54: Product Profile - nintedanib (BIBF-1120) 192
Table 55: nintedanib SWOT Analysis, 2013 195
Table 56: Global Sales Forecasts ($m) for nintedanib, 2012-2022 196
Table 57: Product Profile - afatinib (BIBW-2992) 197
Table 58: afatinib SWOT Analysis, 2013 201
Table 59: Global Sales Forecasts ($m) for afatinib, 2012-2022 202
Table 60: Product Profile - dacomitinib (PF-00299804) 202
Table 61: dacomitinib SWOT Analysis, 2013 206
Table 62: Global Sales Forecasts ($m) for dacomitinib, 2012-2022 207
Table 63: Product Profile - LDK378 208
Table 64: LDK378 SWOT Analysis, 2013 211
Table 65: Global Sales Forecasts ($m) for LDK378, 2012-2022 213
Table 66: Product Profile - Yervoy (ipilimumab) 213
Table 67: Yervoy SWOT Analysis, 2013 216
Table 68: Global Sales Forecasts ($m) for Yervoy, 2012-2022 217
Table 69: Product Profile - nivolumab (BMS936558) 218
Table 70: nivolumab SWOT Analysis, 2013 223
Table 71: Global Sales Forecasts ($) for nivolumab, 2012-2022 224
Table 72: Product Profile - GSK1572932A (MAGE-A3 immunotherapy) 226
Table 73: MAGE-A3 (GSK1572932A ) SWOT Analysis, 2013 228
Table 74: Global Sales Forecasts ($m) for MAGE-A3, 2012-2022 229
Table 75: Product Profile - Halaven (eribulin mesylate) 230
Table 76: Halaven SWOT Analysis, 2013 233
Table 77: Global Sales Forecasts ($m) for Halaven, 2012-2022 234
Table 78: Key Companies in the NSCLC Market, 2013 236
Table 79: Roche/Genentech’s NSCLC Portfolio Assessment, 2013 240
Table 80: Roche/Genentech SWOT Analysis, 2013 240
Table 81: Pfizer’s NSCLC Portfolio Assessment, 2013 242
Table 82: Pfizer SWOT Analysis, 2013 242
Table 83: Bristol-Myers Squibb’s NSCLC Portfolio Assessment, 2013 244
Table 84: BMS SWOT Analysis, 2013 245
Table 85: Eli Lilly’s NSCLC Portfolio Assessment, 2013 247
Table 86: Eli Lilly SWOT Analysis, 2013 247
Table 87: Boehringer Ingelheim’s NSCLC Portfolio Assessment, 2013 249
Table 88: BI SWOT Analysis, 2013 249
Table 89: Novartis NSCLC Portfolio Assessment, 2013 251
Table 90: Novartis SWOT Analysis, 2013 251
Table 91: Global Sales Forecasts ($m) for NSCLC, 2012-2022 253
Table 92: Global NSCLC Market - Drivers and Barriers, 2012-2022 255
Table 93: Sales Forecasts ($m) for NSCLC in the United States, 2012-2022 259
Table 94: Key Events Impacting Sales for NSCLC in the United States, 2012-2022 261
Table 95: NSCLC Market in the United States- Drivers and Barriers, 2012-2022 262
Table 96: Sales Forecasts ($m) for NSCLC in France, 2012-2022 267
Table 97: Key Events Impacting Sales for NSCLC in France, 2012-2022 268
Table 98: NSCLC Market in France - Drivers and Barriers, 2012-2022 269
Table 99: Sales Forecasts ($m) for NSCLC in Germany, 2012-2022 272
Table 100: Key Events Impacting Sales for NSCLC in Germany, 2012-2022 274
Table 101: NSCLC Market in Germany - Drivers and Barriers, 2012-2022 275
Table 102: Sales Forecasts ($m) for NSCLC in Italy, 2012-2022 278
Table 103: Key Events Impacting Sales for NSCLC in Italy, 2012-2022 280
Table 104: NSCLC Market in Italy - Drivers and Barriers, 2012-2022 281
Table 105: Sales Forecasts ($m) for NSCLC in Spain, 2012-2022 284
Table 106: Key Events Impacting Sales for NSCLC in Spain, 2012-2022 285
Table 107: NSCLC Market in Spain - Drivers and Barriers, 2012-2022 286
Table 108: Sales Forecasts ($m) for NSCLC in the UK, 2012-2022 289
Table 109: Key Events Impacting Sales for NSCLC in the UK, 2012-2022 292
Table 110: NSCLC Market in the United Kingdom - Drivers and Barriers, 2012-2022 293
Table 111: Sales Forecasts ($m) for NSCLC in Japan, 2012-2022 297
Table 112: Key Events Impacting Sales for NSCLC in Japan, 2012-2022 299
Table 113: NSCLC Market in Japan - Drivers and Barriers, 2012-2022 299
Table 114: Sales Forecasts ($m) for NSCLC in China, 2012-2022 303
Table 115: Key Events Impacting Sales for Disease NSCLC in China, 2012-2022 305
Table 116: NSCLC Market in China - Drivers and Barriers, 2012-2022 305
Table 117: Sales Forecasts ($m) for NSCLC in India, 2012-2022 310
Table 118: Key Events Impacting Sales for NSCLC in India, 2012-2022 312
Table 119: NSCLC Market in India - Drivers and Barriers, 2012-2022 312
Table 120: Five Year Prevalence 350
Table 121: Key Launch Dates 351
Table 122: Key Patent Expiries 352
Table 123: Physicians Surveyed by Country 371

1.2 List of Figures
Figure 1: 9MM, Age-Standardized (World) Lung Cancer Incidence, Men Ages ?40 Years, 1993-2002 39
Figure 2: 9MM, Age-Standardized (World) Lung Cancer Incidence, Women Ages ?40 Years, 1993-2002 39
Figure 3: Age-Standardized (US, 2000) Lung Cancer Incidence and Mortality, Men and Women, All Ages, US, 1999-2008 43
Figure 4: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, US, 1993-2008 44
Figure 5: Relative Risk of Death from Lung Cancer in Current Smokers, Men and Women, US 45
Figure 6: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, France, 1993-2008 47
Figure 7: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Germany, 1993-2008 48
Figure 8: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Italy, 1993-2008 50
Figure 9: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Spain, 1991-2008 52
Figure 10: Age-Standardized (World) Lung Cancer Incidence and Mortality, Ages ?40 Years, UK, 1993-2008 53
Figure 11: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Japan, 1993-2008 55
Figure 12: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, China, 1993-2008 57
Figure 13: Age-Standardized (World) Lung Cancer Incidence, Men and Women Ages ?40 Years, India, 1993-2002 59
Figure 14: 9MM, Incident Cases of NSCLC, Men and Women Ages ?40 Years, N, Selected Years 2012-2022 71
Figure 15: 9MM, Incident Cases of NSCLC, by Sex, Ages ?40 Years, N, 2012 74
Figure 16: 9MM, Age-Standardized (World) NSCLC Incidence, 2012 75
Figure 17: 9MM, Incident Cases of NSCLC, by Stage at Diagnosis, Men and Women Ages ?40 Years, % and N, 2012 78
Figure 18: 9MM, Incident Cases of NSCLC by Histological Subtype, Men and Women Ages ?40 Years, %, 2012 81
Figure 19: 9MM, Proportion of Smokers Among NSCLC Cases Ages >40 Years and the General Population, Men and Women, %, 2012 82
Figure 20: Smoking History in NSCLC Cases in the 9MM, Men and Women Ages ?40 Years, N, 2012 83
Figure 21: NSCLC Therapeutics - Clinical Trials by Country, 2013 156
Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2012-2022 160
Figure 23: Company Portfolio Gap Analysis in NSCLC, 2012-2022 236
Figure 24: Global Sales for NSCLC by Region, 2012-2022 254
Figure 25: Sales for NSCLC in the United States by Drug Class, 2012-2022 261
Figure 26: Sales for NSCLC in France by Drug Class, 2012-2022 268
Figure 27: Sales for NSCLC in Germany by Drug Class, 2012-2022 274
Figure 28: Sales for NSCLC in Italy by Drug Class, 2012-2022 280
Figure 29: Sales for NSCLC in Spain by Drug Class, 2012-2022 285
Figure 30: Sales for NSCLC in the United Kingdom by Drug Class, 2012-2022 291
Figure 31: Sales for NSCLC in Japan by Drug Class, 2012-2022 298
Figure 32: Sales for NSCLC in China by Drug Class, 2012-2022 304
Figure 33: Sales for NSCLC in India by Drug Class, 2012-2022 311

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research study offers an overview of the multiple sclerosis (MS) disease-modifying product market, including regulatory issues accompanied by detailed analyses and forecasts by product. Its main ...

Sleep Aids : Technologies and Global Markets

Sleep Aids : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

Research on the working of the human brain in relation to sleep is a fairly new area, with many new and novel theories. The discovery of new mechanisms and chemicals in the brain has provided expanding ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.